Legal & General Group PLC Atea Pharmaceuticals, Inc. Transaction History

Legal & General Group PLC

$470 Billion
Q3 2024

A detailed history of Legal & General Group PLC transactions in Atea Pharmaceuticals, Inc. stock. As of the latest transaction made, Legal & General Group PLC holds 7,216 shares of AVIR stock, worth $23,019. This represents 0.0% of its overall portfolio holdings.

Number of Shares

7,216

Previous 7,216 -0.0%

Holding current value

$23,019

Previous $24,000 -0.0%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$3.17 - $4.02 $3,715 - $4,711	1,172 Added 19.39%	7,216 $24,000
Q3 2023 Nov 14, 2023	SELL	$3.0 - $3.79 $3,213 - $4,059	-1,071 Reduced 15.05%	6,044 $18,000
Q2 2023 Aug 14, 2023	SELL	$3.21 - $5.06 $20,081 - $31,655	-6,256 Reduced 46.79%	7,115 $26,000
Q1 2023 May 15, 2023	SELL	$3.0 - $4.97 $47,640 - $78,923	-15,880 Reduced 54.29%	13,371 $44,000
Q3 2022 Nov 14, 2022	BUY	$5.49 - $8.79 $4,084 - $6,539	744 Added 2.61%	29,251 $167,000
Q2 2022 Aug 22, 2022	BUY	$5.33 - $8.18 $85,866 - $131,779	16,110 Added 129.95%	28,507 $203,000
Q3 2021 Nov 15, 2021	BUY	$21.33 - $35.06 $92,081 - $151,354	4,317 Added 53.43%	12,397 $435,000
Q2 2021 Aug 12, 2021	BUY	$19.22 - $59.08 $126,294 - $388,214	6,571 Added 435.45%	8,080 $174,000
Q1 2021 May 17, 2021	SELL	$41.42 - $88.44 $1.32 Million - $2.81 Million	-31,821 Reduced 95.47%	1,509 $93,000
Q4 2020 Feb 12, 2021	BUY	$26.36 - $41.78 $878,578 - $1.39 Million	33,330 New	33,330 $1.39 Million

Others Institutions Holding AVIR

# of Institutions

112

Shares Held

52.4M

Call Options Held

900

Put Options Held

126K

View Full List

About Atea Pharmaceuticals, Inc.

Ticker AVIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,258,600
Market Cap $266M
Description
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...

More about AVIR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.

Account

Legal & General Group PLC Atea Pharmaceuticals, Inc. Transaction History